Overview

Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

Status:
Recruiting
Trial end date:
2023-10-05
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to evaluate type 1 collagen deposition in the lungs following once-daily treatment with PLN-74809 for 12-weeks. This study is occurring at Massachusetts General Hospital.
Phase:
Phase 2
Details
Lead Sponsor:
Pliant Therapeutics, Inc.